Transcranial magnetic stimulator market seen reaching $2.21 billion by 2030

The transcranial magnetic stimulator market is projected to grow from $1.39 billion in 2025 to $1.52 billion in 2026, with the forecast pointing to $2.21 billion by 2030. The report points to rising neurological disorders, broader use of non-drug therapies and faster growth in Asia-Pacific as key drivers.

Why it matters: - The transcranial magnetic stimulator market is expanding as more patients and providers look for non-drug treatments for depression and other neurological conditions. - Market growth could reshape access to outpatient mental health care, neuromodulation services and personalized treatment protocols. - The forecast points to stronger demand in regions investing more heavily in healthcare infrastructure and mental health services.

What happened: - The Business Research Company released a 2026 market report on the global transcranial magnetic stimulator industry. - The report estimates the market will rise from $1.39 billion in 2025 to $1.52 billion in 2026. - The report projects the market will reach $2.21 billion by 2030. - The report places North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - The report includes coverage of South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company also says the 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis.

The details: - The report says the market's 2025-2026 growth reflects a 9.5% compound annual growth rate. - The report says the 2026-2030 forecast reflects a 9.8% compound annual growth rate. - Rising depression rates and other neurological disorders are among the main historical growth drivers. - Broader acceptance of non-pharmacological treatments has supported adoption. - FDA-approved TMS systems have helped expand the market. - Growth in mental health facilities has increased access to treatment. - Wider use of neuromodulation therapies has added momentum. - Future growth is expected to come from use in more neurological conditions, demand for personalized mental health care, growth in outpatient psychiatric services, digital treatment monitoring and greater investment in neuromodulation research. - TMS is being applied to stroke, spasticity, migraine, dementia and movement disorders. - A Parkinson's Foundation study in December 2022 said the number of people living with Parkinson's disease in the US is expected to reach 1.2 million by 2030, up from 930,000 in 2020. - The report highlights repetitive TMS for depression and expanding deep TMS applications. - The report says outpatient mental health care is expanding alongside digital monitoring technologies that improve treatment outcomes.

Between the lines: - The market outlook reflects a shift toward less invasive care as providers try to widen treatment options for patients who do not respond well to medication. - The regional split suggests the next phase of growth may come from markets that are still building access to advanced mental health services. - The emphasis on personalization and digital monitoring suggests TMS providers are competing on outcomes as much as on device capability.

What's next: - The report expects continued expansion in neuromodulation research and broader clinical use of TMS through 2030. - Asia-Pacific growth will likely depend on healthcare investment, government access initiatives and rising diagnosis rates. - The company is offering a free sample and the full market report through its website. - Download a free sample of the report - View the full market report

The bottom line: - Transcranial magnetic stimulation is moving from a niche therapy toward broader use, and the market data points to steady global growth through 2030.